Register for free to listen to this article
Listen with Speechify
0:00
1:00
Bio-Rad Laboratories Inc. and Bruker Corp.

Bio-Rad Laboratories Inc. and Bruker Corp. have jointlylaunched the Lucid Proteomics System, the first system to combine top-down andbottom-up proteomics approaches for biomarker discovery. With both techniqueson one platform, the Lucid Proteomics System accelerates biomarker researchprograms by improving the chances of discovering biomarkers that have clinicalrelevance. The system combines Bio-Rad's ProteinChip surface-enhanced laserdesorption/ionization (SELDI)-based array technology with Bruker'sultrafleXtreme matrix-assisted laser desorption/ionization time-of-flight(MALDI-TOF/TOF) mass spectrometer. The top-down solution includeshigh-throughput protein profiling and identification of biomarker candidates,either by direct on-chip TOF/TOF analysis suitable for small peptides, or byenrichment, purification and digestion followed by TOF/TOF analysis for largerproteins. For the bottom-up approach, Bruker's ultrafleXtreme MALDI-TOF/TOFoffers unmatched performance with high sensitivity, resolution and massaccuracy. 
 
Bio-Rad Laboratories Inc.
(510) 724-7000

Bruker Corp.

(978) 663-3660
 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue